Genmab (NASDAQ:GMAB) seals $1.8B ProfoundBio deal
United States
Genmab (NASDAQ:GMAB) has announced the completion of its $1.8 billion cash acquisition of ProfoundBio.
The acquisition grants Genmab worldwide rights to three clinical-stage candidates, including rinatabart sesutecan (Rina-S), and access to ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms.
This strategic move is aimed at bolstering Genmab's oncology portfolio and reinforcing its efforts in transforming patient care with innovative antibody medicines.